Cited by 690Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Open access

Scagliotti, Giorgio, Hanna, Nasser, Fossella, Frank, Sugarman, Katherine, Blatter, Johannes, Peterson, Patrick, Simms, Lorinda, Shepherd, Frances A.·2009·The Oncologist

DOI 10.1634/theoncologist.2008-0232

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0232

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citation
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Flagged first, then by citations

Show all 51 references

5 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)

Sorted by citations

Items 301–400 of 687

Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions
Custodio, A., & de Castro, J. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.08.003 · Cited by 19
The search for improved systemic therapy of non-small cell lung cancer—What are today's options?
Früh, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.020 · Cited by 20
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
Tamiya, M., Tamiya, A., Kaneda, H., Nakagawa, K., Yoh, K., Goto, K., Okamoto, H., Shimokawa, T., Abe, T., Tanaka, H., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0715-7 · Cited by 19
TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
Takeuchi, A., Oguri, T., Yamashita, Y., Sone, K., Fukuda, S., TAKAKUWA, O., Uemura, T., Maeno, K., Fukumitsu, K., Kanemitsu, Y., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12882 · Cited by 20
Determining factors of endobronchial ultrasound-guided transbronchial needle aspiration specimens for lung cancer subtyping and molecular testing
Sun, J., Zhang, Y., Xie, F., Mao, X., Zheng, X., Li, Y., & Zhu, L. (2019) · Endoscopic Ultrasound · doi:10.4103/eus.eus_8_19 · Cited by 19
Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer
Zhang, W., Gao, Z., Zeng, G., Xie, H., Liu, J., Liu, N., & Wang, G. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.11.022 · Cited by 19
UFT and S-1 for treatment of primary lung cancer
Tanaka, F., Wada, H., & Fukushima, M. (2010) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-009-0498-x · Cited by 19
Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era
Gupta, N., Sekar, A., & Rajwanshi, A. (2015) · Journal of Cytology · doi:10.4103/0970-9371.171219 · Cited by 19
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
Corrales, L., Nogueira, A., Passiglia, F., Listì, A., Caglevic, C., Giallombardo, M., Raez, L. E., Santos, E. S., & Rolfo, C. D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00013 · Cited by 21
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status
Minami, S., Kijima, T., Hamaguchi, M., Nakatani, T., Koba, T., Takahashi, R., Takeuchi, Y., Kida, H., Nagatomo, I., Yamamoto, S., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.022 · Cited by 18
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)
Schnabel, P. A., Smit, E. F., de Castro, J., Leniewski-Kmak, K., Aerts, J. G. J. V., Kraaij, K., Visseren‐Grul, C., Dyachkova, Y., Taipale, K., Girvan, A. C., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.001 · Cited by 18
Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architecture
Lee, L. H., Tambasco, M., Otsuka, S., Wright, A., Klimowicz, A. C., Petrillo, S. K., Morris, D. G., Magliocco, A. M., & Bebb, D. G. (2014) · Micron · doi:10.1016/j.micron.2014.07.005 · Cited by 19
Lung Cancer Working Group Report
Saijo, N., Fukuoka, M., Thongprasert, S., Ichinose, Y., Mitsudomi, T., Mok, T. S. K., Ohe, Y., Park, K., & Wu, Y.-L. L. C. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq121 · Cited by 18
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options
Popat, S., Mellemgaard, A., Reck, M., Hastedt, C., & Griebsch, I. (2017) · Future Oncology · doi:10.2217/fon-2016-0493 · Cited by 18
Comparative survival analysis of platinum‐based adjuvant chemotherapy for early‐stage squamous cell carcinoma and adenocarcinoma of the lung
Hsiao, S., Chen, W., Chung, C., Chou, Y., Lin, S., Hong, S., Chang, J., Chang, T., & Chien, L. (2022) · Cancer Medicine · doi:10.1002/cam4.4570 · Cited by 18
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
Galetta, D., Rossi, A., Pisconti, S., & Colucci, G. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.642372 · Cited by 18
Maintenance therapy in non-small-cell lung cancer
Stinchcombe, T. E., & West, H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61598-1 · Cited by 18
Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer
El‐Khoury, V., Béland, M., Schritz, A., Kim, S., Nazarov, P. V., Gaboury, L. A., Sertamo, K., Bernardin, F., Batutu, R., Antunes, L., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0200-0 · Cited by 18
A Comparative Texture Analysis Based on NECT and CECT Images to Differentiate Lung Adenocarcinoma from Squamous Cell Carcinoma
Liu, H., Jing, B., Han, W., Long, Z., Mo, X., & Li, J. (2019) · Journal of Medical Systems · doi:10.1007/s10916-019-1175-y · Cited by 18
Comparative effectiveness of three platinum‐doublet chemotherapy regimens in elderly patients with advanced non–small cell lung cancer
Zhu, J., Sharma, D. B., Chen, A. B., Johnson, B. E., Weeks, J. C., & Schrag, D. (2013) · Cancer · doi:10.1002/cncr.28022 · Cited by 17
The Utility of Fine-Needle Aspiration in the Diagnosis of Primary and Metastatic Tumors to the Lung: a Retrospective Examination of 1,032 Cases
Adams, J., & Wu, H. H. (2012) · Acta Cytologica · doi:10.1159/000342935 · Cited by 17
Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non–Small-Cell Lung Cancer
Dy, G. K., Bogner, P. N., Tan, W., Demmy, T. L., Farooq, A., Chen, H., Yendamuri, S. S., Nwogu, C. E., Bushunow, P. W., Gannon, J. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000062 · Cited by 17
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
Kim, Y. H., Hirabayashi, M., Togashi, Y., Hirano, K., Tomii, K., Masago, K., Kaneda, T., Yoshimatsu, H., Otsuka, K., Mio, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1910-2 · Cited by 17
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study
Moro‐Sibilot, D., Vergnenégre, A., Smit, E. F., Toy, E., Parente, B., Schmitz, S. H., Kraaij, K., Visseren‐Grul, C., Soldatenkova, V., Arellano, J., et al. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.525489 · Cited by 17
Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung
Naito, Y., Kubota, K., Ohmatsu, H., Goto, K., Niho, S., Yoh, K., & Ohe, Y. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq781 · Cited by 17
Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
Xing, P., Mu, Y., Wang, Y., Hao, X., Zhu, Y., Hu, X., Wang, H., Liu, P., Lin, L., Wang, Z., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12650 · Cited by 16
Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Melosky, B. L. (2018) · Current Oncology · doi:10.3747/co.25.3839 · Cited by 17
Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non–small-cell Lung Cancer in China
Li, X., Abbas, M., Li, Y., Teng, Y., Fang, Y., Yu, S., Wen, Y., Wang, L., & Shi, M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.02.004 · Cited by 17
Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
Melosky, B. L. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00038 · Cited by 18
Different Cutoff Values for Thyroid Transcription Factor-1 Antibodies in the Diagnosis of Lung Adenocarcinoma
Smits, A. J. J., Vink, A., Tolenaars, G., Herder, G. J. M., & Kummer, J. A. (2014) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000099 · Cited by 17
Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni, L., Vavalà, T., & Novello, S. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0429-x · Cited by 17
Efficient pan-cancer whole-slide image classification and outlier detection using convolutional neural networksPreprint
Bilaloglu, S., Wu, J. Y., Fierro, E., Sanchez, R., Ocampo, P., Razavian, N., Coudray, N., & Tsirigos, A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/633123 · Cited by 17
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer
Treat, J., Edelman, M. J., Belani, C. P., Socinski, M. A., Monberg, M., Chen, R., & Obasaju, C. K. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.02.011 · Cited by 16
The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer
Kim, Y. S., Sun, J., Ahn, J. S., Ahn, M., & Park, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.011 · Cited by 16
Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
YANG, M., Fan, W., Pu, X., Liu, F., Meng, L., & Wang, J. (2013) · Oncology Letters · doi:10.3892/ol.2013.1688 · Cited by 16
Parameters for individualizing systemic therapy in non-small cell lung cancer
Gadgeel, S. M., Coté, M. L., Schwartz, A. G., Matherly, L. H., Wozniak, A. J., & Bepler, G. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.10.001 · Cited by 17
Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis
Qi, W., Tang, L., He, A., Shen, Z., & Yao, Y. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1155-9 · Cited by 16
Second-Line Chemotherapy and Beyond for Non–Small Cell Lung Cancer
Durm, G. A., & Hanna, N. H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.002 · Cited by 16
Self-citation
Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non–Small-Cell Lung Cancer: The JIPANG Study Protocol
Yamamoto, N., Kenmotsu, H., Yamanaka, T., Nakamura, S., & Tsuboi, M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.020 · Cited by 16
Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer
Micke, P., Botling, J., Mattsson, J. S. M., Planck, M., Tran, L., Viðarsdóttir, H., Nodin, B., Jirström, K., & Brunnström, H. (2019) · Scientific Reports · doi:10.1038/s41598-018-37722-0 · Cited by 16
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Kim, Y. S., Cho, E. K., Woo, H. S., Hong, J., Ahn, H. K., Park, I., Sym, S. J., Kyung, S. Y., Kang, S. M., Park, J.-W., et al. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.307 · Cited by 16
A ccuracy of cytology in sub typing non small cell lung carcinomas
Patel, T., Shah, M. G., Gandhi, J., & Patel, P. (2017) · Diagnostic Cytopathology · doi:10.1002/dc.23730 · Cited by 16
Combined double CK5/P63 stain: Useful adjunct test for diagnosing pulmonary squamous cell carcinoma
Fatima, N., Cohen, C., Lawson, D., & Siddiqui, M. T. (2011) · Diagnostic Cytopathology · doi:10.1002/dc.21678 · Cited by 16
Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer
Chung, F., Lee, K.-Y., Fang, Y., Shieh, M.-H., Lin, S., Yu, C.-T., Lo, Y. L., Lin, T., Kuo, C.-H. S., Feng, P., et al. (2011) · Chemotherapy · doi:10.1159/000321037 · Cited by 15
Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology
Zinner, R., Saxman, S. B., Peng, G., Monberg, M., & Ortuzar, W. I. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.045 · Cited by 15
The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors
Krawczyk, P. A., Kowalski, D. M., Wojas‐Krawczyk, K., Mlak, R., Jaśkiewicz, P., Kucharczyk, T., Winiarczyk, K., Krzakowski, M. J., & Milanowski, J. (2012) · Chemotherapy · doi:10.1159/000336143 · Cited by 15
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Kim, Y. H., Hirabayashi, M., Kosaka, S., Nikaidoh, J., Yamamoto, Y., Shimada, M., Toyazaki, T., Nagai, H., Sakamori, Y., & Mishima, M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2142-9 · Cited by 15
Subclassification of Non-Small Cell Lung Cancer by Cytologic Sampling: A Logical Approach with Selective Use of Immunocytochemistry
Kimbrell, H. Z., Gustafson, K. S., Huang, M., & Ehya, H. (2012) · Acta Cytologica · doi:10.1159/000338519 · Cited by 15
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel
Maïo, M. D., Krzakowski, M. J., Fougeray, R., Kowalski, D. M., & Gridelli, C. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.013 · Cited by 15
Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life
Schuette, W., Tesch, H., Büttner, H., Krause, T., Soldatenkova, V., & Stoffregen, C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-14 · Cited by 15
Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib
Selaru, P., Tang, Y., Huang, B., Polli, A., Wilner, K. D., Donnelly, E. T., & Cohen, D. P. (2016) · Clinical and Translational Science · doi:10.1111/cts.12388 · Cited by 16
Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis
Armoiry, X., Tsertsvadze, A., Connock, M. J., Royle, P., Meléndez‐Torres, G. J., Souquet, P.-J., & Clarke, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199575 · Cited by 15
Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles
Visser, S., Hou, J., Bezemer, K., de Vogel, L. L., Hegmans, J. P., Stricker, B. H. C., Philipsen, S., & Aerts, J. G. J. V. (2019) · BMC Cancer · doi:10.1186/s12885-019-5645-x · Cited by 15
Prognostic Significance of the Neutrophil/Lymphocyte Ratio in Patients undergoing Treatment with Nivolumab for Recurrent Non-Small-Cell Lung Cancer
Rapoport, B. L., Theron, A. J., Vorobiof, D., Langenhoven, L., Hall, J. M., Eeden, R. I. V., Smit, T., Chan, S. W., Botha, M. C., Raats, J., et al. (2020) · Lung Cancer Management · doi:10.2217/lmt-2020-0014 · Cited by 15
MicroRNA Gene Dosage Alterations and Drug Response in Lung Cancer
Enfield, K. S. S., Stewart, G. L., Pikor, L. A., Alvarez, C. E., Lam, S. C., Lam, W. L., & Chari, R. (2011) · BioMed Research International · doi:10.1155/2011/474632 · Cited by 15
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
Langer, C. J., Paz-Ares, L. G., Wozniak, A. J., Gridelli, C., de Marinis, F., Pujol, J.-L., Antonio, B. S., Chen, J., Liu, J., Oton, A. B., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.003 · Cited by 15
Self-citation
Machine Learning in Diagnosis and Prognosis of Lung Cancer by PET-CT
Yuan, L., An, L. K., Zhu, Y., Duan, C., Kong, W., Jiang, P., & Yu, Q. (2024) · Cancer Management and Research · doi:10.2147/cmar.s451871 · Cited by 16
Impact of harmonization and oversampling methods on radiomics analysis of multi-center imbalanced datasets: application to PET-based prediction of lung cancer subtypes
Du, D., Shiri, I., Yousefirizi, F., Salmanpour, M. R., Lv, J., Wu, H., Zhu, W., Zaidi, H., Lu, L., & Rahmim, A. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00750-7 · Cited by 14
Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All
Caponi, S., Vasile, E., Ginocchi, L., Tibaldi, C., Borghi, F., D’Incecco, A., Lucchesi, M., Caparello, C., Andreuccetti, M., & Falcone, A. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.040 · Cited by 14
New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS
Ceppi, P., Papotti, M., & Scagliotti, G. V. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0017-4 · Cited by 14
Self-citation
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study
Gridelli, C., Ardizzoni, A., Barni, S., Crinò, L., Caprioli, A., Piazza, E., Lorusso, V., Barbera, S., Zilembo, N., Gebbia, V., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.011 · Cited by 14
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
Passaro, A., Cortesi, E., & de Marinis, F. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.120 · Cited by 14
Immunohistochemistry
Mani, H., & Zander, D. S. (2012) · CHEST Journal · doi:10.1378/chest.11-3327 · Cited by 14
PROFILE 1014: lessons for the new era of lung cancer clinical research.
Noonan, S. A., & Camidge, D. R. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.05.02 · Cited by 14
Histological Subtype Classification of Non-Small Cell Lung Cancer with Radiomics and 3D Convolutional Neural Networks
Liang, B., Tong, C., Nong, J., & Zhang, Y. (2024) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-024-01152-4 · Cited by 17
The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management.
Tang, Y., He, Z., Zhu, Q., & Qiao, G. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.09.15 · Cited by 13
Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer
Tsuchiya, T., Fukuda, T., Furuiye, M., & Kawabuchi, K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.002 · Cited by 13
Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome
Walter, R. F. H., Mairinger, F. D., Werner, R., Vollbrecht, C., Hager, T., Schmid, K. W., Wohlschlaeger, J., & Christoph, D. C. (2016) · Oncotarget · doi:10.18632/oncotarget.7737 · Cited by 13
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape
Lazzari, C., Karachaliou, N., Gregorc, V., Bulotta, A., González‐Cao, M., Verlicchi, A., Altavilla, G., Rosell, R., & Santarpía, M. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1326822 · Cited by 13
Pemetrexed in Nonsquamous Non–Small Cell Lung Cancer
Gyawali, B., & Prasad, V. K. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1944 · Cited by 13
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto, H., Onitsuka, T., Shimokawa, H., & Hanagiri, T. (2010) · PubMed · Cited by 13
Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer
Novello, S., Pimentel, F. L., Douillard, J., O'Brien, M. E. R., von Pawel, J., Eckardt, J. R., Liepa, A. M., Simms, L., Visseren‐Grul, C., & Paz-Ares, L. G. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181eaf30f · Cited by 13
Self-citation
Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI
Hu, R., Shi, S., Qi, J.-L., Tian, J., Tang, X., Liu, G.-F., & Chang, C. (2014) · Medical Oncology · doi:10.1007/s12032-014-0063-z · Cited by 13
Whole-tumor histogram analysis of multi-parametric MRI for differentiating brain metastases histological subtypes in lung cancers: relationship with the Ki-67 proliferation index
Zhang, B., Zhou, F., Zhou, Q., Xue, C., Ke, X., Zhang, P., Han, T., Deng, L., Jing, M., & Zhou, J. (2023) · Neurosurgical Review · doi:10.1007/s10143-023-02129-7 · Cited by 12
Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer
Holgersson, G., Bergström, S. N., Bergqvist, M., Nyman, J., Hoye, E., Helsing, M., Friesland, S., Holgersson, M., Birath, E., Ekman, S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.011 · Cited by 12
Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care
Patel, J. D., Paz-Ares, L. G., Zinner, R., Barlési, F., Koustenis, A. G., & Obasaju, C. K. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.013 · Cited by 12
Study on combination therapy for lung cancer through pemetrexed‐loaded mesoporous polydopamine nanoparticles
Xu, J., Xu, W., Wang, Z., & Jiang, Y. (2022) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37436 · Cited by 12
Das fortgeschrittene Bronchialkarzinom – was gibt es Neues in der Diagnostik und Therapie?
Rothschild, S. I. (2015) · Praxis · doi:10.1024/1661-8157/a002058 · Cited by 12
Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
Kwon, J.-H., Kim, K., Sung, J. H., Suh, K. J., Lee, J. Y., Kim, J., Kim, J., Lee, J., Kim, J. W., Kim, Y. J., et al. (2019) · Cells · doi:10.3390/cells8121538 · Cited by 12
Pemetrexed in head and neck cancer: A systematic review
Argiris, A. E., Pennella, E. J., Koustenis, A. G., Hossain, A. M., & Obasaju, C. K. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.01.007 · Cited by 12
Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment
Colombi, D., Lauro, E. D., Silva, M., Manna, C., Rossi, C., Filippo, M. D., Zompatori, M., Ruffini, L., & Sverzellati, N. (2013) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2013.12021 · Cited by 12
Second-Line Therapy in Non–Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens
Zer, A., & Leighl, N. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.4270 · Cited by 12
Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer
Fleitas, T., Martínez‐Sales, V., Gómez‐Codina, J., Martín, M. S., & Reynés, G. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0549-x · Cited by 12
Maintenance or Consolidation Therapy for Non–Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects
Zhang, C., Huang, C., Wang, J., Wang, X., & Li, K. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.002 · Cited by 11
Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma
Zhang, C., Yang, H., Lang, B., Yu, X., Xiao, P., Zhang, D., Fan, L., & Zhang, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s165660 · Cited by 11
A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors
Karim, N. A., Ullah, A., Wang, H., Shoukier, M., Pulliam, S., Ahmed, K., Patel, N., & Morris, J. C. (2022) · Current Oncology · doi:10.3390/curroncol29120744 · Cited by 11
Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?
Vandermeer, R., Chambers, S., Dam, A. V., Cutz, J.-C., Goffin, J. R., & Ellis, P. M. (2015) · Current Oncology · doi:10.3747/co.22.2526 · Cited by 11
Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
Geiger, S., Schlemmer, M., Heinemann, V., & Stemmler, H. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833dbbfe · Cited by 11
Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer
Okamoto, I., Takeda, K., Daga, H., Miyazaki, M., Yonesaka, K., Kiyota, H., Tsurutani, J., Ueda, S., Ichikawa, Y., Takeda, M., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.02.007 · Cited by 11
Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
Clements, K. M., Peltz, G., Faries, D. E., Lang, K. M., Nyambose, J., Earle, C. C., Sugarman, K. P., Taylor, D. C. A., Thompson, D. A., & Marciniak, M. D. (2010) · Chemotherapy Research and Practice · doi:10.1155/2010/524629 · Cited by 11
Self-citation
A Phase II Study of Pemetrexed in Chemotherapy-naive Elderly Patients Aged >=75 years with Advanced Non-squamous Non-small-cell Lung Cancer (HANSHIN Oncology Group 003)
Hattori, Y., Iwasaku, M., Satouchi, M., Nishiyama, A., Korogi, Y., Otsuka, K., Fujita, S., Katakami, N., Mori, M., Nishino, K., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt159 · Cited by 11
Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed
Sakamori, Y., Kim, Y. H., Yoshida, H., Nakaoku, T., Nagai, H., Yagi, Y., Ozasa, H., & Mishima, M. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.452 · Cited by 11
miR-124-3p Regulates FGF2–EGFR Pathway to Overcome Pemetrexed Resistance in Lung Adenocarcinoma Cells by Targeting MGAT5
Cai, J., Huang, J., Wang, W., Zeng, J., & Wang, P. (2020) · Cancer Management and Research · doi:10.2147/cmar.s274192 · Cited by 11
Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules
Chen, J., Li, X., & Wei, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s45148 · Cited by 11
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
Okamoto, I., Shimizu, T., Miyazaki, M., Tsurutani, J., Ichikawa, Y., Terashima, M., Takeda, M., Fumita, S., Ohki, E., Kimura, N., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9565-5 · Cited by 10
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer
Comella, P., Chiurì, V. E., Cataldis, G. D., Filippelli, G., Maiorino, L., Vessia, G., Cioffi, R., Mancarella, S., Putzu, C., Greco, E., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.008 · Cited by 10
Does the number of cycles of neoadjuvant therapy affect the efficacy of neoadjuvant chemoimmunotherapy for non‐small cell lung cancer in locally advanced stage? Retrospective experience based on a single center
Zhu, D., Huang, Z., Xiao, K., Bian, D., Zhang, J., Zhang, Z., Zhu, S., Yin, L., Zhu, J., & Zhang, P. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13971 · Cited by 10
C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma
Jacobsen, B. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.621 · Cited by 10
Clinical development of new formulations of cytotoxics in solid tumors
Azim, H. A., & Awada, A. H. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328351fb29 · Cited by 10

Authors: Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
Affiliations: University of Turin (IT)
Indiana University Indianapolis (US)
The University of Texas MD Anderson Cancer Center (US)
Eli Lilly (United States) (US)
Eli Lilly (Germany) (DE)
Eli Lilly (Canada) (CA)
University of Toronto (CA)
Corresponding author: Scagliotti, Giorgio
ORCID: Scagliotti, Giorgio
Hanna, Nasser
Peterson, Patrick
Shepherd, Frances A.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2009-02-16
Volume: 14
Issue: 3
Pages: 253-263
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2008-0232
OpenAlex: W2139939379
Cited by: 690
References: 51
Citations by year: 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
FWCI: 72.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
MeSH terms: Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks